Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q16637 (
SMA
)
8,107
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Autosomal recessive spinal muscular atrophy (SMA) is a common, fatal neuromuscular disease caused by homozygous absence of the
SMN1
gene in approximately 94% of patients. However, a highly homologous SMN2 gene exists in the same chromosome interval, centromeric to
SMN1
, and hampers detection of
SMN1
. We present a new, rapid, simple, and highly reliable method for detecting the
SMN1
deletion/conversion and for determining the copy numbers of the
SMN1
and SMN2 genes by DHPLC. We analyzed
SMN1
/SMN2 gene exon 7 deletion/conversion by DHPLC. A total of 25 patients with spinal muscular atrophy lacking the
SMN1
gene as well as 309 control individuals from the general population and the family members of patients with SMA were analyzed. By DHPLC analysis, we could detect the SMA-affected cases efficiently just by recognizing an SMN2-only peak. Furthermore, after specific primer amplification and adjustment of the oven temperature, all of the SMA carriers with an
SMN1
/SMN2 ratio not equal to 1 could be identified unambiguously by this simple and efficient detection system. To calculate the total
SMN1
/SMN2 gene dosages further, we developed a specific multiplex competitive PCR protocol by simultaneously amplifying the CYBB gene (X-linked), the
KRIT1
gene (on chromosome arm 7q), and the
SMN1
/SMN2 gene ratio by DHPLC. By applying this technique, we could successfully designate all of the genotypes with different
SMN1
/SMN2 gene copy numbers, including equal and unequal amounts of
SMN1
and SMN2. We demonstrated that DHPLC is a fast and reliable tool for detection of carriers of SMA.
...
PMID:Quantitative analysis of SMN1 and SMN2 genes based on DHPLC: a highly efficient and reliable carrier-screening test. 1583 10
We established a universal multiplex PCR and CE to calculate the copy number of
survival motor neuron
(
SMN1
and SMN2) genes for clinical screening of spinal muscular atrophy (SMA). In this study, one universal fluorescent primer was designed and applied for multiplex PCR of
SMN1
, SMN2 and two internal standards (CYBB and
KRIT1
). These amplicons were separated by conformation sensitive CE. Mixture of hydroxyethyl cellulose and hydroxypropyl cellulose were used in this CE system. Our method provided the potential to separate two 390-bp PCR products that differ in a single nucleotide. Differentiation and quantification of
SMN1
and SMN2 are essential for clinical screening of SMA patients and carriers. The DNA samples included 22 SMA patients, 45 parents of SMA patients (obligatory carriers) and 217 controls. For evaluating accuracy, those 284 samples were blind-analyzed by this method and denaturing high pressure liquid chromatography (DHPLC). Eight of the total samples showed different results. Among them, two samples were diagnosed as having only SMN2 gene by DHPLC, however, they contained both
SMN1
and SMN2 by our method. They were further confirmed by DNA sequencing. Our method showed good agreement with the DNA sequencing. The multiplex ligation-dependent probe amplification (MLPA) was used for confirming the other five samples, and showed the same results with our CE method. For only one sample, our CE showed different results with MLPA and DNA sequencing. One out of 284 samples (0.35%) belonged to mismatching. Our method provided a better accurate method and convenient method for clinical genotyping of SMA disease.
...
PMID:Universal multiplex PCR and CE for quantification of SMN1/SMN2 genes in spinal muscular atrophy. 1937 9